Lexicon Pharmaceuticals
LXRX
127 hedge funds and large institutions have $220M invested in Lexicon Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 34 closing their positions.
236% more call options, than puts
Call options by funds: $547K | Put options by funds: $163K
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
2.5% more ownership
Funds ownership: 79.84% → 82.35% (+2.5%)
7% less funds holding
Funds holding: 137 → 127 (-10)
26% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 34
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less capital invested
Capital invested by funds: $453M → $220M (-$233M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.35M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.84M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.18M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.54M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$17.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.65M |
| 3 |
Millennium Management
New York
|
-$2.2M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$1.26M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.18M |
LXRX Hedge Fund Activity: Q4 2024 in Review
127 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2024, worth a combined $220M — down 51% from $453M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LXRX and 25 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 45 added.
The largest buyer was Point72 Asset Management, adding an estimated $9.35M. The largest seller was OrbiMed, exiting entirely with an estimated $17.3M sold.
- 127 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2024, down from 137 in Q3 2024.
- Funds reported $220M of Lexicon Pharmaceuticals stock for Q4 2024, down 51% quarter-over-quarter.
- 25 funds opened new Lexicon Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of -9 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2024 was Point72 Asset Management, an estimated $9.35M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2024 was OrbiMed, an estimated $17.3M sold.
Based on aggregated 13F filings for Q4 2024.